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Highlights
 Combining morphology and biology represents the most useful
approach to select candidates for LT in the context of HCC.
 To maintain post-LT 5-year incidence of “HCC-related death” <30%,
Metroticket 2.0 criteria had to be restricted in some cases.
 Adding mRECIST criteria to Metroticket 2.0 led to correct reclas-
sification of 9.4% of patients with “HCC-related death”.
 This additional information can be used to better judge the suit-
ability of candidates for LT following neoadjuvant therapies.
Authors
Alessandro Cucchetti, Matteo Serenari,
Carlo Sposito, ., Giorgio Ercolani,
Antonio Daniele Pinna, Matteo Cescon
Correspondence
aleqko@libero.it (A. Cucchetti).
Lay summary
In the context of liver transplantation
for patients with hepatocellular car-
cinoma, prediction models are used to
ensure that the risk of recurrence after
transplantation is acceptably low. The
Metroticket 2.0 model has been pro-
posed as an accurate predictor of
“tumour-related death” after liver
transplantation. In the present study,
we show that its accuracy can be
improved by incorporating informa-
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for hepatocellular carcinoma (HCC), prediction models are used
to ensure that the risk of post-LT recurrence is acceptably low.
However, the weighting that ‘response to neoadjuvant therapies’
should have in such models remains unclear. Herein, we aimed
to incorporate radiological response into the Metroticket 2.0
model for post-LT prediction of “HCC-related death”, to improve
its clinical utility.
Methods: Data from 859 transplanted patients (2000-2015) who
received neoadjuvant therapies were included. The last radio-
logical assessment before LT was reviewed according to the
modified RECIST criteria. Competing-risk analysis was applied.
The added value of including radiological response into the
Metroticket 2.0 was explored through category-based net
reclassification improvement (NRI) analysis.
Results: At last radiological assessment prior to LT, complete
response (CR) was diagnosed in 41.3%, partial response/stable
disease (PR/SD) in 24.9% and progressive disease (PD) in 33.8% of
patients. The 5-year rates of “HCC-related death” were 3.1%, 9.6%
and 13.4% in those with CR, PR/SD, or PD, respectively (p <0.001).
Log10AFP (p <0.001) and the sum of number and diameter of the
tumour/s (p <0.05) were determinants of “HCC-related death” for
PR/SD and PD patients. To maintain the post-LT 5-year incidence
of “HCC-related death” <30%, the Metroticket 2.0 criteria were
restricted in some cases of PR/SD and in all cases with PD,
correctly reclassifying 9.4% of patients with “HCC-related death”,
at the expense of 3.5% of patients who did not have the event.
The overall/net NRI was 5.8.words: Hepatocellular carcinoma; Liver transplant; Neoadjuvant therapy;
vival; mRECIST.
eived 11 July 2019; received in revised form 21 February 2020; accepted 10 March
0; available online 20 March 2020
orresponding author. Address: Department of Medical and Surgical Sciences –
EC, Alma Mater Studiorum - University of Bologna, Via Albertoni 15, 40138
gna, Italy.
ail address: aleqko@libero.it (A. Cucchetti).
s://doi.org/10.1016/j.jhep.2020.03.018
Journal of Hepatology 2Metroticket 2.0 framework can improve its predictive ability. The
additional information provided can be used to better judge the
suitability of candidates for LT following neoadjuvant therapies.
Lay summary: In the context of liver transplantation for patients
with hepatocellular carcinoma, prediction models are used to
ensure that the risk of recurrence after transplantation is
acceptably low. The Metroticket 2.0 model has been proposed as
an accurate predictor of “tumour-related death” after liver
transplantation. In the present study, we show that its accuracy
can be improved by incorporating information relating to the
radiological responses of patients to neoadjuvant therapies.
© 2020 European Association for the Study of the Liver. Published by
Elsevier B.V. All rights reserved.Introduction
Hepatocellular carcinoma (HCC) represents one of the leading
indications for liver transplantation (LT).1 The main obstacle to
applying LT to all patients with HCC is the need to minimize the
post-operative recurrence of the tumour. Several studies have
shown how radiological features and biological surrogates, such
as alpha-fetoprotein (AFP) and response to pre-LT neoadjuvant
therapies, can provide important information on candidate se-
lection, prioritization and, ultimately, survival after LT.2–11 The
goal should be to incorporate this additional information into
refined transplantability criteria.
Within the prognostic indexes proposed in the modern clin-
ical scenario, the Metroticket 2.0 criteria were developed under a
competing-risk framework. Such an approach overcomes a
fundamental bias when analysing post-LT outcomes, especially
in the presence of highly effective antivirals for HCV.12–14 In fact,
the primary outcome of interest in the present setting should be
death due to HCC recurrence, whereas deaths due to other
causes, such as hepatitis recurrence, are competing events which
could mask the real prognostic impact of pre-transplant
radiological and biological features on HCC recurrence and020 vol. 73 j 342–348
tumour-related survival.3,14 However, the weight of the response
to neoadjuvant therapies remained a partially unsolved question
in these criteria model, as well as in other criteria currently
proposed, such as the AFP-French model or the HALT-HCC.2,4 On
one hand, Metroticket 2.0 showed that the radiological behav-
iour prior to LT correlated with pre-transplant tumour size,
number and AFP, which formed the final prognostic model, but
on the other hand it did not specify whether the final tumour
burden was the consequence of a partial response to neo-
adjuvant therapies, or of a stable or progressive disease (PD) of
an untreated tumour or after neoadjuvant treatments. To be
unequivocal, a single vital T2 tumour with moderate AFP levels,
resulting from a down-staging protocol, has a different biology to
a similar tumour that is stable after neoadjuvant therapy or re-
sults from PD. In the first, we can perceive a favourable biology,
whereas, in the latter case, we can perceive an unfavourable
aggressiveness with negative post-transplant consequences.
Thus, the aim of the present study was to re-evaluate the
relationship between tumour features and radiological behav-
iour prior to LT, to refine the Metroticket 2.0 criteria by incor-
porating the “biological history” of transplanted tumours.
Materials and methods
Part of the cohort of the Metroticket 2.0 model was reviewed and
updated, the present cohort included only cases which formed
the derivation dataset. After update, the study population started
with 1,137 patients with known HCC who underwent LT for HCC
between January 2000 and December 2015 at 3 tertiary referral
hepato-biliary and transplant centres in Italy. Incidental HCCs
were not included in the present data collection. Priority policy
and transplantation criteria were those already published in the
Metroticket 2.0.3 From the starting population, 149 patients were
excluded because of incomplete dataset, and/or because of the
absence of pre-LT radiological evaluation, resulting in a popula-
tion of 988 patients. Only patients who received neoadjuvant
treatments were retained, leading to the exclusion of 129 un-
treated patients. Consequently, the final study population con-
sisted of 859 patients. The use of present data was approved by
the National Cancer Institute Institutional Review Board and
fulfilled the Regulation (EU) 2016/679 of the European Parlia-
ment and of the Council of 27 April 2016 on the protection of
natural persons regarding the processing of personal data.
Neoadjuvant therapies
For all patients, the history of neoadjuvant therapies, was
collected. Oncological data were obtained at referral to the
tumour board meetings and after their application prior to LT
using the last available imaging data. The decision for any
eventual specific neoadjuvant therapy was decided during such
multidisciplinary groups based on tumour stage and liver func-
tion. The adopted treatments did not fully accomplish the in-
ternational guideline suggestions but were individualized based
on patient and tumour features, as well as the perceived prob-
ability of success. Hepatic resection was offered to HCC patients
deemed resectable in the setting of a liver transplant program,
considering both “salvage” and “bridge” perspectives.
Radiological assessment
At radiology, only nodules with a maximum diameter of at least
1 cm counted as HCC nodules, providing that the international
criteria released during the study period were fulfilled. TheJournal of Hepatology 2radiological assessment before LT was accomplished according to
the modified RECIST (mRECIST) criteria.15 The mRECIST data
were prospectively collected, apart from in patients enlisted
before 2010, in whom they were retrospectively reviewed. In
addition, the maximum diameter of the active nodule/s was
recorded as in RECIST 1.116 for use in the Metroticket 2.0 model.
Candidates were followed during waiting list within a 3-month
radiological surveillance which included contrast-enhanced ul-
trasound (CEUS) with a second-generation ultrasonography
contrast agent (SonoVue, Bracco Imaging S.p.A., Milano, Italy),
tri- or quadriphasic CT scan or MR imaging, depending on clinical
indications and suitability. Complete radiological response (CR)
was diagnosed when imaging showed the absence of any intra-
tumoural enhancement during arterial phase.15
The inter-observer (inter-centre) agreement was explored
through the cross-check of mRECIST of 180 random cases be-
tween the 3 centres, to provide an estimation of the bias related
to this issue. This sample was representative of the entire study
population with a 95% of confidence and a 10% margin of error.
The final mRECIST evaluation considered for all the analyses was
that of the corresponding centre which transplanted the patient.
Pathological assessment
At histology, the explanted livers were sampled to evaluate all
macroscopically suspect nodules, and neoplastic masses were
thoroughly examined. The complete absence of any residual vital
tumour tissue defined the complete pathological response (CPR).
When tumour tissue was detected, the number and size of active
HCC nodules was reported together with the presence or
absence of microscopic vascular invasion. In the present study,
tumour grading was not included because of too much missing
data. In cases where LT was performed early (<90 days) after
hepatic resection due to post-operative liver failure, the patho-
logical findings of the resected specimen and the explanted liver
were considered altogether.
Metroticket 2.0 framework
Patients with CR after neoadjuvant treatments were considered
as having 0 nodules with 0 diameter at pre-LT assessment. As
already reported, the sum of number and size of the largest
tumour (i.e. 1 nodule of 6 cm = up-to-7) was considered in the
subsequent competing-risk regression.3 The Metroticket 2.0
criteria were constructed to maintain the 5-year “HCC-related
death” incidence below 30% to allow for confidence bands. This
safety threshold was fulfilled in 3 pre-LT radiological clinical
situations, defining the Metroticket 2.0 criteria IN:
1. HCC at pre-LT radiology within the up-to-7 criteria, if AFP
<200 ng/ml;
2. HCC at pre-LT radiology within the up-to-5 criteria, if AFP
200–400 ng/ml;
3. HCC at pre-LT radiology within the up-to-4 criteria, if AFP
400–1000 ng/ml;Follow-up and outcome definitions
All survival analyses fulfilled the competing-risk concept. Date of
death/last censoring, date of diagnosis of HCC recurrence and
cause of death were collected. For recurrence-free survival, death
without evidence of HCC recurrence was considered as a
competing event. Patient survival was the primary outcome
measure where death was defined as “HCC-related” when020 vol. 73 j 342–348 343
Table 1. Clinical features of recipients who received neoadjuvant therapies.
Clinical features n = 859
Age [years (median; IQR)] 57 (52–62)
Male, n (%) 754 (87.8)
Hepatitis C, n (%) 489 (56.9)
Hepatitis B, n (%) 275 (32.0)
Alcohol, n (%) 167 (19.4)
Other, n (%) 35 (4.1)
Within Milan criteria at diagnosis/before listing (%) 751 (87.4)
Number of neoadjuvant therapies (median; IQR)* 1 (1–2)
Research Article Liver Transplantationconsequent to a documented HCC recurrence, either intra- or
extrahepatic, submitted or not to additional non-transplant
therapies, which unequivocally lead to a progressive worsening
of performance status until death. Death because of tumour
recurrence was also defined when liver function worsened as a
consequence of intra-hepatic tumour spread, such as massive
liver involvement or development of tumoural macroscopic
vascular invasion. All the other causes of death were defined as
“non-tumour-related” and considered as competing events.Number of therapies >−3, n (%) 104 (12.1)
Time from diagnosis to LT [months (median; IQR)] 13.1 (8.0–22.7)
Time spent in waiting list [months (median; IQR)] 4.3 (2.2–10.0)
>6 months, n (%) 341 (39.7)
Time from last radiological assessment and LT [months
(median; IQR)]
2.2 (1.0–4.1)
Complete Response, n (%) 355 (41.3)
Partial Response/Stable Disease, n (%) 214 (24.9)
Progressive disease, n (%)† 290 (33.8)
Number of vital tumours
None, n (%) 355 (41.3)
Single nodule, n (%) 258 (33.6)
2-3 nodules, n (%) 207 (24.1)
>3 nodules, n (%) 39 (4.5)
Largest vital tumour at pre-LT radiology [cm, (median;
IQR)]†
2.1 (1.5–3.0)
Within Milan criteria at pre-LT radiology (%) 803 (93.5)
Last AFP before LT [ng/ml (median; IQR)] 8.1 (4.0–22)
Log10 AFP [ng/ml (median; IQR)] 0.91 (0.60–1.34)
Complete pathological response at histology, n (%) 214 (24.9)
Recurrence-rate, %‡
1-year (95% CI) 4.0 (2.8–5.5)
3-year (95% CI) 10.4 (8.4–12.6)Statistical analysis
No missing data were present. Continuous variables were re-
ported as medians and IQRs. The Kruskal-Wallis and the Fisher
exact tests were adopted as appropriate. Survival probabilities
were estimated using the Kaplan-Meier method. The last
censoring was on January 2019. Competing-risk analyses were
performed using the methodologies provided by Scrucca and
Fine & Gray17,18 and repeated for each mRECIST criteria consid-
ered. Such stratification was adopted to overcome biases gener-
ated by collinearity between Metroticket 2.0 criteria and
mRECIST criteria.15,16 The added value of incorporating radio-
logical response into the Metroticket 2.0 criteria was reported
through the category-based net reclassification improvement
(NRI),19 defining “HCC-related death” within 5 years from LT as
events, and patients alive at 5 years as non-events. Analyses
were performed using STATA and R-Project. Finally, mRECIST
agreement between centres on the sample of 180 random cases
was assessed using k-Cohen.5-year (95% CI) 12.5 (10.3–14.9)
HCC-related death, %‡
1-year (95% CI) 1.5 (0.8–2.6)
3-year (95% CI) 5.9 (4.4–7.7)
5-year (95% CI) 8.1 (6.4–10.2)
FP, alpha-fetoprotein; HCC, hepatocellular carcinoma; LT, liver transplantation.
*Refer to Supplementary table for details.
†Diameters of non-vital tumours were excluded from the calculation.
‡Calculated through competing-risk analysis, with death without recurrence/for
other causes as competing events.Results
The baseline features of 859 patients are summarized in Table 1.
Median follow-up was 5 years (IQR 3.0–8.1). During this time, 111
patients had post-transplant HCC recurrence and 208 deaths
were registered, of which 81 were tumour related. Recurrence
and “HCC-related death” rates are detailed in Table 1.
The median time from last radiological assessment and LT was
of 2.2 months (IQR 1.0–4.1). The last radiological assessment was
performedwith CT in 636 patients (74.0%), withMR in 197 (23.0%)
and with CEUS in 26 patients (3.0%). CR was diagnosed in 41.3%,
partial response/stable disease (PR/SD) in 24.9%, and PD in 33.8%.
Competing-risk analysis (Fig. 1A) showed that patients with
CR had 1-, 3- and 5-year “HCC-related death” rates of 0.3%, 1.8%
and 3.1%, respectively; patients with PR/SD had rates of 1.9%, 6.1%
and 9.6% and patients with PD had rates of 2.8%, 10.9% and 13.4%,
respectively (p <0.001).Complete radiological response
The 355 patients with CR at last radiological assessment prior to
LT, received a total of 523 neoadjuvant treatments (Table S1 and
S2). The median time from last radiological assessment to LT was
2.3 months (IQR 1.1–4.4). At final histology, a CPR was demon-
strated in 46.5% of cases. As depicted in Fig. 1B, recipients with
CPR had a 1-, 3- and 5-year rates of “HCC-related death” of 0%,
0.6% and 1.4%, respectively (corresponding to 2 patients who
developed bone metastases within 18 months from LT). In
contrast, recipients without CPR had a 1-, 3- and 5-year rates of
“HCC-related death” of 0.5%, 2.7% and 4.4%, respectively (p =
0.006). The pre-LT AFP was not found related to this survival
endpoint (Table 2).344 Journal of Hepatology 2Partial response/stable disease
The 214 patients with PR/SD at last radiological assessment
received a total of 326 neoadjuvant therapies (Table S1 and S2).
The median time from last radiological assessment and LT was of
2.0 months (IQR 1.0–3.9). At final histology, the absence of HCC
was observed in 9.4% of cases. Competing-risk regression
(Table 2) showed Log10AFP (p <0.001) and the sum of number
and diameter of the tumour/s (p <0.001) as determinants of
“HCC-related death”.Progressive disease
The 290 patients showing PD prior to LT received a total of 479
neoadjuvant therapies (Table S1 and S2). The median time from
last radiological assessment and LT was 2.2 months (IQR 0.9–4.0).
At final histology, the absence of HCC was observed in 10.0% of
cases. Competing-risk regression (Table 2) confirmed Log10AFP
(p <0.001) and the sum of number and diameter of the tumour/s
(p=0.004) asdeterminantsof “HCC-relateddeath” in thesepatients.Radiological response within the Metroticket 2.0 framework
The original Metroticket 2.0 criteria were reviewed based on the
hazard ratios of each sub-group. To accomplish a cumulative020 vol. 73 j 342–348
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Fig. 1. Cumulative incidences of “HCC-related death”. (A) Stratified by last
mRECIST assessment and by (B) absence/presence of complete pathological
response at final histology in 355 patients showing complete radiological
response at last pre-LT imaging. Error bars represent standard errors. p values
derived from log-rank test for competing-risk analyses.18 CPR, complete
pathological response; CR, complete response; HCC, hepatocellular carcinoma;
LT, liver transplantation; mRECIST, modified RECIST; PD, progressive disease;
PR/SD, partial response/stable disease.incidence of “HCC-related death” of <30% 5 years after transplant,
the criteria were adjusted as reported in Fig. 2. Dimensional
criteria were restricted in some cases of PR/SD and in all cases of
PD prior to LT. Consequently, 35 patients within Metroticket 2.0
criteria did not fulfil the present radiological-adjusted criteria.
These 35 patients had 1-, 3-, and 5-year rates of “HCC-related
death” of 2.9%, 17.4% and 25.0%, respectively.
As detailed in the Table 3, in comparison to the Metroticket
2.0 criteria, the inclusion of radiological response resulted in a
correct reclassification of 9.4% of patients who died from “HCC-
related death” within 5 years from LT but at the expense of 3.5%
of patients who did not have the event, however, the overall NRI
was positive at 5.8. In comparison to the Milan criteria, theTable 2. Coefficients resulting from stratified competing-risk analysis on HCC
mRECIST Number + diameter p va
CR n.a.
PR/SD 0.236 (0.106–0.365) <0.
PD 0.188 (0.061–0.315) 0.
The baseline cumulative hazard at 5-year for PR/SD was 0.010109 and for PD was 0.016
The predicted 5-year probability of “HCC-related death” can be obtained solving the
diameter + coefficient x Log10AFP)] and 5-year = 1-exp(-pi).
The median AFP in patients with CR was 6.8 ng/ml (IQR 3.1–17.6), in patients with PR/
AFP, alpha-fetoprotein; CR, complete response; HCC, hepatocellular carcinoma; mRE
response/stable disease.
Journal of Hepatology 2application of radiological response determined a correct
reclassification of 10.9% of patients who died from “HCC-related
death”within 5 years from LT and of 2.0% of patients who did not
have the event, with an overall NRI of 12.9.
Inter-centre agreement on radiological response
In the sample of 180 radiological evaluations for the assessment
of mRECIST agreement, the proportion of concordant pairs was
77.8%, with a kappa of 0.67 (95% CI 0.55–0.79) indicating sub-
stantial agreement between centres (Table 4). When PR and SD
were pooled, the proportion of concordant pairs increased to
84.4% with a kappa of 0.75 (95% CI 0.62–0.87).
Discussion
Assessing LT eligibility in patients with HCC is an evolving field of
research.20,21 The need for accurate outcome prediction is crucial to
ensure that the waiting list includes those candidates who will
benefit most, while excluding those with an unfavourable prog-
nosis.22,23 The present study fulfils the efforts of identifying
“transplantable tumours” as accurately as possible through the
estimation of the impact of response to neoadjuvant therapies.
Recent studies focused on the combination of tumour features and
biologicalmarkers, and, on this background, the AFP-Frenchmodel,
the HALT-HCC and the Metroticket 2.0 models were the most reli-
able in the clinical setting.2–4 These models shared common fea-
tures but were each unique. The AFP-French model was based on
tumour number/size and AFP at listing2 but no data on response to
neoadjuvant therapywere reportedor considered. In theHALT-HCC
model the history of neoadjuvant therapy was recorded (59.6% of
the derivation cohort received locoregional therapy) but the result
was not significant for overall survival prediction in the final
regression model.4 The Metroticket 2.0 depicted the relationships
between the radiological behaviour through RECIST 1.1 criteria and
tumour features at transplant, using only the latter for HCC-specific
post-LT survival.3 Present results suggest that the inclusion of
mRECISTcriteriawithin theMetroticket 2.0 framework can provide
useful information to refine outcome prediction.
In 2018, the Metroticket 2.0 calculator was developed with
the aim of predicting post-LT HCC-specific survival.3 This survival
endpoint was introduced to appropriately weigh the oncologic
determinants of post-LT death in the presence of other con-
founding causes of death. This calculator showed good accuracy
on an Eastern series of patients and was generalizable to
different populations.3 However, the aim of that study was to
provide a prognostic tool that combined both simplicity of use
and accuracy, and for this reason, at that stage, the variables
taken into account in the model were only tumour morphology
(sum of size and number) and AFP. The relationships between
radiological features of treated and untreated HCCs and pre-LT-related death.
lue Log10 AFP p value
– 0.172 (−0.748–1.092) 0.714
001 0.934 (0.424–1.443) <0.001
004 0.870 (0.524–1.216) <0.001
729.
following equation: pi = [baseline cumulative hazard x exp (coefficient x number +
SD was 8.6 (IQR 4.0–22.0) and in patients with PD was 10.0 (IQR 5.0–32.0).
CIST, modified RECIST; n.a., not applicable; PD, progressive disease; PR/SD, partial
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Fig. 2. Careful restriction of Metroticket 2.0 criteria for transplantable HCC.
Based on morphology (largest vital tumour size + number of vital tumour
nodules) and biology (AFP and last radiological mRECIST assessment) after
neoadjuvant therapies. The darkest areas describe a 5-year “HCC-related death”
above the safety threshold of 30%. The black bold line represents the original
Metroticket 2.0 criteria. AFP, alpha-fetoprotein; HCC, hepatocellular carcinoma;
mRECIST, modified RECIST; PD, progressive disease; PR/SD, partial response/
stable disease.
Table 4. Overall distribution of mRECIST evaluation pairs from the 3
participating centres.
CR PR SD PD
CR 35 4 1 0
PR 3 21 2 0
SD 2 4 3 0
PD 0 1 3 11
The number of observed agreements was 70/90 pairs (77.8%). The kappa was 0.67
(95% CI 0.55–0.79) indicating substantial agreement between centres (k = 0.00-0.20:
slight agreement; 0.21-0.40: fair agreement; 0.41-0.60: moderate agreement; 0.61-
0.80: substantial agreement; 0.81-1.00: almost perfect agreement.
Numbers represent the sum of pairs of mRECIST evaluations between centres #1 vs.
#2, #2 vs. #3 and #1 vs. #3.
CR, complete response; mRECIST, modified RECIST; PD, progressive disease; PR/SD,
partial response/stable disease.
Research Article Liver Transplantationtumour number and diameter were described, but not included
in the calculator because of their correlations.3 Nevertheless,
neoadjuvant locoregional therapies are commonly applied inTable 3. NRI of inclusion of mRECIST evaluation into the Metroticket 2.0
model in comparison to original Metroticket 2.0 and Milan criteria.
Criteria Metroticket + mRECIST
Events* IN OUT Total
Metroticket 2.0 IN 40 6 46
OUT 0 18 18
Total 40 24 64
Non-events IN OUT Total
Metroticket 2.0 IN 368 15 383
OUT 1 11 12
Total 369 26 395
Events correctly reclassified by mRECIST assessment vs. Metroticket 2.0
Higher = 6/64 = 9.4%; Lower = 0/64 = 0%; NRI events = 9.4 – 0 = 9.4%
Non - events correctly reclassified by mRECIST assessment vs.Metroticket 2.0
Higher = 15/395= 3.8%; Lower = 1/395 = 0.3%; NRI events = 0.3 – 3.8 = −3.5%
Overall NRI = 9.4 – 3.5 = 5.8
Criteria Metroticket + mRECIST
Events* IN OUT Total
Milan criteria IN 39 8 47
OUT 1 16 17
Total 40 24 64
Non-events IN OUT Total
Milan criteria IN 356 5 361
OUT 13 21 34
Total 369 26 395
Events correctly reclassified by mRECIST + Metroticket vs. Milan criteria
Higher = 8/64 = 12.5%; Lower = 1/64 = 1.6%; NRI events = 12.5 – 1.6 = 10.9%
Non - events correctly reclassified by mRECIST + Metroticket vs. Milan
criteria
Higher = 5/395= 1.3%; Lower = 13/395 = 3.3%; NRI events = 3.3 – 1.3 = 2.0%
Overall NRI = 10.9 + 2.0 = 12.9
NRI of Metroticket 2.0 vs. Milan criteria is 12.9 – 5.8 = 7.1.
HCC, hepatocellular carcinoma; LT, liver transplantation; mRECIST, modified RECIST;
NRI, net reclassification improvement.
*NRI is calculated among patients who died for HCC recurrence within 5 years from
LT (events = 64) and those who were alive without recurrence at this temporal
endpoint (non-events = 395).
346 Journal of Hepatology 2HCC candidates, as bridging or down-staging procedures, and the
response to these treatments can suggest a more, or less,
aggressive disease from a biological point of view, which de-
serves consideration.5–7 Lee et al. recently showed that the
incidence of post-LT recurrence, analysed through a competing-
risk approach, was significantly worse in patients who did not
respond to pre-LT neoadjuvant therapies, being up to about 26%
at 5 years.5 On the contrary, the same figure was <10% in cases
showing complete or partial response according to mRECIST
criteria.5 Two analyses of the US Multicenter HCC Transplant
Consortium, among more than 3,000 patients receiving or not
receiving pre-LT locoregional therapies, highlighted that the
response to neoadjuvant treatment and unfavourable wait-list
AFP were the main determinants of post-LT recurrence, result-
ing in a hazard ratio of ~2.1.6,7 In the present study, all this in-
formation was embedded within the Metroticket 2.0 criteria
through the inclusion of mRECIST, in order to provide some
additional clinically useful information.
First, we observed that pre-LT radiological assessment pro-
vided a satisfactory discrimination of “HCC-related death” 5 years
after LT, with rates of 3.1%, 9.6% and 13.4% for patients showing
CR, PR/SD and PD, respectively, at the time of transplant. These
data confirm that progression on the waiting list represents the
clinical expression of a more aggressive tumour behaviour, that
in a non-negligible percentage of cases might turn into post-LT
death because of recurrence.5–7,24 However, the observation of
PD prior to LT should not be considered as a contraindication to
LT, it simply calls for prudence in the selection of these patients
by narrowing the dimensional criteria. This restriction would
allow patients with PD to obtain an outcome not far from that of
patients with PR/SD and with larger tumour burden. On the
other hand, patients showing CR because of neoadjuvant thera-
pies at the time of LT had a very low risk of post-LT “HCC-related
death”, and may be considered as “ideal candidates”, providing
that the initial HCC stage was consistent with an indication to LT.
Additionally, patients showing CR also represented a category for
which it is not necessary to provide any particular priority on the
waiting list.22,23,25
Determinants of HCC-specific survival were the usual, as
shown in Table 2. However, stratification for radiological
response, necessary to minimize possible collinearity between
mRECIST and dimensional assessments in the original Metro-
ticket 2.0 criteria, led to some interesting results. First, AFP did
not turn out to be related to “HCC-related death” for patients
showing CR to neoadjuvant therapies. This result was almost
expected considering that a negligible proportion of these pa-
tients had AFP >20 ng/ml. Conversely, both tumour size +020 vol. 73 j 342–348
number and AFP turned out to be consistently associated with
“HCC-related death” in patients with PR/SD and PD. The absolute
effect of size + number and AFP was similar among PR/SD pa-
tients and PD patients, as suggested by similar coefficients, but
their relative impact on outcomes increased with the worsening
of response to neoadjuvant therapies, as suggested by increasing
baseline cumulative hazard (for PR/SD was about 0.0101 and for
PD was 0.0167). Overall, when analysed in the context of the
AFP-adjusted criteria proposed in the Metroticket 2.0, the pre-
sent results confirmed the validity of the original criteria for
most patients who get to LT with a PR/SD, but also suggest
restricting the indication for some patients with PR/SD and for all
patients showing PD.
The end-result of the adoption of radiological response
assessment was that an additional 9.4% of patients who died
because of “HCC-related death” within 5 years from LT would
have been identified compared to using the Metroticket 2.0
application alone. This increased sensitivity would be paid for by
a decrease in specificity of 3.5%, but the positive overall NRI of 5.8
suggests that the benefits outweigh the harms of such an
approach, providing clinical utility. A brief explanation and
comparison of this value is necessary at this point. The NRI value
derives from considering its 2 reported components (events and
non-events), an identical point estimate of this statistic may have
different interpretations depending on its components.19,26 The
present NRI value showed that this was positive, thus, that the
new classification had positive effects. As a comparator, the AFP-
French model showed in its training cohort a NRI of 11.4 over
Milan criteria, as the end-result of a correct reclassification of
6.9% of patients who had HCC recurrence within 5 years from LT,
at the expense of 4.5% of patients who did not have the event.
The current model showed an NRI of 12.9 over Milan criteria as
the result of a correct reclassification of 10.9% of events and of
2.0% of non-events. However, higher NRI does not necessarily
mean higher accuracy24 and details about reclassification of
events and non-events among risk classes were reported herein
to indicate the direction and the magnitude of reclassification.
Another interesting finding of the present study was the
observation that radiological diagnosis of CR can be consid-
ered quite inaccurate. The median time from last radiological
assessment and LT was <3 months in most cases, and radio-
logical assessment was performed by dedicated radiologists at
high volume centres. However, in the 355 patients showing
radiological absence of vital tumours, CPR was confirmed in
only 46.5% of cases. These findings are in line with most
prospective and retrospective studies, in which a radiological
CR was confirmed by a CPR in 50–82.4% of cases, highly
depending on the type and number of pre-LT
treatments.6,9,24,27,28 The accuracy of the diagnosis of com-
plete radiological response acquires importance in the light of
post-transplant outcomes, with an incidence of “HCC-related
death” at 5 years of only 1.4% when CR was confirmed by CPR.
Interestingly, the present end-result was identical to that
previously reported by Agopian et al. in 501 transplanted pa-
tients.29 This low radiological accuracy will probably cause a
disagreement between radiological PR/SD/PD and final path-
ological evaluation of tumour burden. In this sense, patho-
logical assessment would provide the optimal information to
estimate the risk of recurrence, as in the original Metroticket
published in 2009, but lacks clinical applicability from an
intention-to-treat point of view before LT. Consequently, andJournal of Hepatology 2at present, clinical decisions should still be based on an
imperfect system which already includes misclassification
probabilities.
This study has some limitations: first, this is a retrospective
study in which a part of the radiological evaluation had been re-
assessed according to mRECIST because this data was not avail-
able before 2010. This aspect, together with a lack of central
radiological review, may weaken radiological response evalua-
tion. The large sample size and the homogeneous radiological
protocols among the 3 participating centres can counterbalance
this potential bias. In fact, as suggested by the FDA Clinical Trial
Imaging Endpoint Process Standards 2018, centralized image
interpretationprocessesmay providemore verifiable anduniform
reader training, but centralized image interpretation is not always
critical when using some aspects of quantitative imaging.30 If the
quantitativemeasure is widely performed and reported in clinical
medicine, as for mRECIST evaluation, centralization would have
been necessary if radiological centres with little experience in the
evaluation of these criteria had been involved in the present
study.30 Nevertheless, the analysis of mRECIST agreement be-
tween the participating centres suggested that a source of un-
certainty is present, albeit unavoidable in clinical practice. It
should be noted however, thatwhenpooling PR/SD cases, as in the
present study, the proportion of agreements was up to 84.4%,
which represent a clinically useful result.
Second, the assessment of radiological response included
CEUS, CT and MR, depending on clinical indications and suit-
ability. Consequently, and especially for patients submitted to
transarterial chemoembolization, mRECIST assessment would
not be ideal.27 Since radiological protocols and expertise were
similar between participating centres, it is unlikely that a
centralized image review would increase accuracy in the mRE-
CIST assessment, as stated before. Present data simply represent
the end-results of the common clinical practice where it would
be unlikely to follow all patients with MR. Finally, radiological
evaluation and post-LT outcomes were not analysed according to
the type of locoregional or surgical treatment applied. This
choice was made upfront, because the selection of treatments in
the pre-LT period is a dynamic process that depends on several
variables that might change over this period, and that cannot be
fully considered in a retrospective study. The scope of the pre-
sent study that was to provide a static pre-LT selection criterion
that might guide clinicians in the decision process when a donor
is available, namely AFP and last radiological evaluation in terms
of mRECIST criteria and morphological tumour characteristics.
In conclusion, we have gone a step further in the selection
process for LT, highlighting that identifiable patients with PR/SD
or PD should be carefully considered based on morphological/
biological criteria at the time of LT, to maintain an acceptably low
risk of post-LT “HCC-related death”.
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